CL vs FRPT: How Colgate-Palmolive and Freshpet Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CL and FRPT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CL and FRPT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.

Full CL guide

Freshpet makes fresh, refrigerated food for dogs and cats and sells it through company-owned branded refrigerators placed inside retailers including Walmart, Target, Kroger, Costco, Publix, Petco, PetSmart and Tractor Supply. The model is unusual for a food company: Freshpet buys, installs, services and owns the fridge, which is both the distribution asset and the merchandising unit, and it manufactures nearly everything itself across three kitchen complexes in Bethlehem, Pennsylvania and Ennis, Texas. That vertical integration is why capital spending has run heavy for a decade (roughly $150 million planned in 2026) and why operating leverage arrives in steps rather than smoothly, as new lines come online and then fill up.

Full FRPT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CL drivers: Oral-care leadership and emerging markets; Hill's Pet Nutrition growth.
• FRPT drivers: Household penetration and buy rate, not price; Capacity coming online at Ennis.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. For FRPT, the competitive set changed in 2025 and 2026 and has not settled: The Farmer's Dog moved onto Walmart.com, Hill's launched a fresh line, and Costco introduced Kirkland fresh pet food, all attacking the premium position Freshpet built alone.

Pick CL if you believe its drivers more; FRPT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CL and FRPT guides.

CL. Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.

FRPT. The gap between the operating result and the share price is the whole story here: the stock sits roughly 55% below its late-2024 peak while revenue, margins and cash flow have all improved. Reported net income figures are noisy because of tax valuation-allowance movements and a ~$4.5 million equity-investment gain in Q2 2026, so adjusted EBITDA is the cleaner comparison across periods. Anyone sizing the multiple should note that heavy capex means EBITDA overstates free cash flow, and that ~$150 million of annual capital spending is a real claim on it.

Headline figures (approximate, early 2026): CL shows revenue (ttm) ~$20 billion, operating margin ~20-21%, net income (ttm) ~$2.7 billion, dividend yield ~2-2.5% (Dividend King); FRPT shows revenue (ttm) ~$1.18 billion, with Q2 2026 net sales of ~$305.6 million, up ~15.5% year over year, 2026 guidance Net sales growth of ~10% to 12% (~$1.21 billion to $1.23 billion), raised in August 2026 from ~8% to 11%, adjusted ebitda ~$52.2 million in Q2 2026 (~17.1% margin); full-year guidance raised to ~$210 million to $220 million, margins Adjusted gross margin ~48.6% in Q2 2026 versus ~46.9% a year earlier; guided to improve ~100 to 150 basis points for the year.

CL and FRPT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CL and FRPT exposure against your real portfolio. It is not an investment adviser.